济川药业
(600566)
| 流通市值：273.63亿 | | | 总市值：275.41亿 |
| 流通股本：9.16亿 | | | 总股本：9.22亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,805,134,511.2 | 4,034,400,209.97 | 2,402,545,954.32 | 9,654,537,192.67 |
| 营业收入 | 5,805,134,511.2 | 4,034,400,209.97 | 2,402,545,954.32 | 9,654,537,192.67 |
| 二、营业总成本 | 3,879,965,357.38 | 2,717,305,015.54 | 1,594,276,317.54 | 6,516,457,726.29 |
| 营业成本 | 1,204,122,608.31 | 823,982,793.25 | 453,698,653.45 | 1,783,993,372.03 |
| 税金及附加 | 92,793,745.97 | 63,590,546.22 | 38,740,096.81 | 146,238,497.23 |
| 销售费用 | 2,190,344,923.91 | 1,610,143,804.25 | 989,645,386.93 | 4,006,536,051.96 |
| 管理费用 | 301,233,712 | 189,579,615.62 | 91,736,719.04 | 372,779,034.03 |
| 研发费用 | 296,861,461.95 | 208,204,374.23 | 114,221,835.9 | 464,400,198.6 |
| 财务费用 | -205,391,094.76 | -178,196,118.03 | -93,766,374.59 | -257,489,427.56 |
| 其中:利息费用 | 22,746,776.34 | 15,879,320.48 | 7,550,518.45 | 17,583,918.49 |
| 其中:利息收入 | 229,024,263.75 | 194,656,242.46 | 101,596,444.51 | 276,084,305.02 |
| 加:公允价值变动收益 | 86,459,260.4 | 51,999,388.12 | 16,232,067.88 | 14,603,985.81 |
| 加:投资收益 | 30,728,253.75 | 15,800,332 | 14,744,804.02 | 81,723,599.77 |
| 资产处置收益 | 188,213.44 | -4,733.85 | -5,944.01 | 130,280.19 |
| 信用减值损失(新) | 51,746,773.19 | 49,799,886.79 | 41,482,263.78 | 3,225,543.75 |
| 其他收益 | 25,365,926.32 | 23,101,784.18 | 5,202,341.01 | 20,372,895.9 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,119,657,580.92 | 1,457,791,851.67 | 885,925,169.46 | 3,258,135,771.8 |
| 加:营业外收入 | 115,101,979.63 | 110,900,820.88 | 103,965,583.27 | 41,644,609.74 |
| 减:营业外支出 | 1,261,923.35 | 1,033,976.52 | 100,588.51 | 2,690,791.34 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,233,497,637.2 | 1,567,658,696.03 | 989,790,164.22 | 3,297,089,590.2 |
| 减:所得税费用 | 326,151,566.57 | 226,364,771.13 | 143,002,860.11 | 470,026,598.95 |
| 六、净利润 | 1,907,346,070.63 | 1,341,293,924.9 | 846,787,304.11 | 2,827,062,991.25 |
| 持续经营净利润 | 1,907,346,070.63 | 1,341,293,924.9 | 846,787,304.11 | 2,827,062,991.25 |
| 归属于母公司股东的净利润 | 1,902,829,554.86 | 1,338,306,956.4 | 845,266,461.66 | 2,822,781,164.62 |
| 少数股东损益 | 4,516,515.77 | 2,986,968.5 | 1,520,842.45 | 4,281,826.63 |
| (一)基本每股收益 | 2.07 | 1.45 | 0.92 | 3.08 |
| (二)稀释每股收益 | 2.07 | 1.45 | 0.92 | 3.08 |
| 九、综合收益总额 | 1,907,346,070.63 | 1,341,293,924.9 | 846,787,304.11 | 2,827,062,991.25 |
| 归属于母公司股东的综合收益总额 | 1,902,829,554.86 | 1,338,306,956.4 | 845,266,461.66 | 2,822,781,164.62 |
| 归属于少数股东的综合收益总额 | 4,516,515.77 | 2,986,968.5 | 1,520,842.45 | 4,281,826.63 |
| 公告日期 | 2024-10-26 | 2024-08-24 | 2024-04-20 | 2024-04-10 |
| 审计意见(境内) | | | | 标准无保留意见 |